SpaceX Dragon departs ISS carrying one of the most medically significant science payloads, including bioprinted tissue and cancer treatment materials.

A SpaceX Cargo Dragon spacecraft departed the International Space Station on June 16, carrying a payload of significant medical research materials, including bioprinted organ and cartilage tissue, DNA-engineered cancer treatment materials, and blood-forming stem cells. The spacecraft is targeting a splashdown in the Pacific Ocean early June 17.¹

One of the key investigations involves the return of bioprinted tissues, which are part of ongoing research to utilize microgravity as a fabrication environment for biological structures. This research aims to enhance the development of tissues that could be used in regenerative medicine.

Another experiment focuses on DNA-inspired materials engineered for new cancer treatments, allowing researchers to study how these materials interact with tumor structures similar to those encountered by oncologists in patients. The ISS provides a unique environment for such studies, as microgravity modulates biological pathways that govern cell behavior.

Additionally, the mission includes the return of hematopoietic stem cells grown in orbit, which have shown changes in microgravity, including a 20 to 30 percent increase in cell diameter and a 1.5- to 2-fold increase in proliferation rate. These findings could have implications for blood cell generation and cancer treatment.

The upgraded Cargo Dragon 2 design, used for this mission, features 12 powered lockers to maintain temperature-controlled conditions for biological samples during descent, ensuring the integrity of time-sensitive cargo.

Time-sensitive samples will be transported by helicopter from the recovery ship to Kennedy Space Center, allowing researchers to receive them within four to nine hours of splashdown.